|
Week of study
|
---|
|
0
|
4
|
8
|
12
|
p valuea
|
---|
Weight (kg)
|
Placebo
|
84.8 ± 0.9
|
85.7 ± 0.9
|
86.0 ± 0.9
|
85.1 ± 0.9
| |
HMB-FA
|
85.0 ± 0.9
|
85.8 ± 0.9
|
86.7 ± 0.9
|
86.9 ± 0.9#
|
0.003
|
DXA LBMb (kg)
|
Placebo
|
67.1 ± 1.1
|
68.0 ± 1.1
|
70.0 ± 1.1
|
69.2 ± 1.1
| |
HMB-FA
|
67.1 ± 1.1
|
70.1 ± 1.1#
|
72.2 ± 1.1#
|
74.5 ± 1.1#
|
0.001
|
DXA fat (kg)
|
Placebo
|
17.6 ± 1.7
|
16.8 ± 1.7
|
16.0 ± 1.7
|
15.9 ± 1.7
| |
HMB-FA
|
17.9 ± 1.7
|
15.7 ± 1.7
|
14.4 ± 1.7#
|
12.5 ± 1.7#
|
0.0003
|
Quadriceps depth (mm)
|
Placebo
|
50.2 ± 2.1
|
52.2 ± 2.1
|
52.5 ± 2.1
|
52.6 ± 2.1
| |
HMB-FA
|
50.2 ± 2.1
|
53.1 ± 2.1
|
55.60 ± 2.1#
|
57.4 ± 2.1#
|
0.0001
|
- Adjusted least square mean ± SD for n = 11 HMB-FA-supplemented (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented participants
-
aProbability of treatment by time difference between the placebo and HMB-FA treatments over the 12-week study. The mixed model ANOVA in SAS was used with the main effects of treatment, time and treatment by time, with the value for week 0 used as a covariate of treatment
-
b
DXA LBM Dual X-Ray absorptiometry determined lean body mass
-
#Significantly different than corresponding placebo, t test (p < 0.05)